Vol. 6 No. 4 (2026): April
Reimbursement Reviews

Encorafenib (Braftovi)

decorative image of the issue cover

Published April 30, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Encorafenib (Braftovi), 75 mg capsules taken orally.
  • Indication: Encorafenib, in combination with cetuximab and mFOLFOX6, for the treatment of patients with mCRC with a BRAF V600E mutation, as detected by a validated test.